-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Rostafuroxin
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/156722-18-8.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 156722-18-8 |
| Description | Rostafuroxin is a Na+/K+ ATPase modulator that treats hypertension by normalizing renal Na+/K+ ATPase pump function. |
Product Information
| Synonyms | PST-2238; PST 2238; (3S,5R,8R,9S,10S,13S,14S,17S)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol |
| IUPAC Name | (3S,5R,8R,9S,10S,13S,14S,17S)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol |
| Molecular Weight | 374.521 |
| Molecular Formula | C23H34O4 |
| Canonical SMILES | CC12CCC(CC1CCC3C2CCC4(C3(CCC4(C5=COC=C5)O)O)C)O |
| InChI | InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1 |
| InChIKey | AEAPORIZZWBIEX-DTBDINHYSA-N |
| Boiling Point | 451.3±45.0°C at 760 mmHg |
| Flash Point | 226.7±28.7 °C |
| Purity | 98.07% |
| Density | 1.226±0.06 g/cm3 |
| Solubility | Soluble in DMSO. |
| Appearance | White Solid |
| Shelf Life | 2 years |
| Storage | Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -20°C for long term (months to years). |
| Complexity | 609 |
| Exact Mass | 374.24570956 |
| Index Of Refraction | 1.591 |
| In Vitro | Rostafuroxin (PST 2238) competitively inhibits Ouabain (HY-B0542) binding and signaling. Rostafuroxin antagonizes the molecularand functional effects of Ouabain by reversing the ouabain-induced, Src-dependent Na+,K+-ATPase phosphorylation and activation. Rostafuroxin (0.125-128 μM; for 24 h post treatment) has less than 20% reduction in cell viability in A549 cells and HSAEC. Rostafuroxin inhibits the expression of RSV-GFP in HSAEC (IC50=1.8 μM) and A549 cells (IC50=14.8 μM). Rostafuroxin displaced [3H]Ouabain from the dog kidney Na+,K+-ATPase receptor (IC50=1.5 nM), is devoid of cardiac inotropic activity in isolated guinea pig atria, and shows no affinity up to 10-4 M with general (R1, R2, a1, a2, A1, A2, M1, M2, H1, H2, 5-HT1, 5-HT2, Ca2+ channels, TXA2/PGH2, PAF, GABAA, GABAB, DA-NE-5-HT uptake, glutammate,glycine, benzodiazepine) and hormonal (estrogenic, progestinic, androgenic, mineralcorticoid) receptors. |
| In Vivo | Rostafuroxin (PST 2238; 1 mg/kg/day; gavage; for 3 weeks) decreases SBP and improves acetylcholine-induced relaxation. |
| PSA | 73.83000 |
| Target | Na+/K+ ATPase; RSV |
| Vapor Pressure | 0.0±1.2 mmHg at 25°C |
| XLogP3-AA | 3.3 |
